Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 5nilotinib 4Cytarabine 4fludarabine 3Methotrexate 3Imatinib Mesylate 3Dasatinib 3Busulfan 3fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2AP 1903 reagent 2sargramostim 1ruxolitinib 1merphos 1amsonic acid 1Whole-Body Irradiation 1Vincristine 1Valproic Acid 1Thiotepa 1Tacrolimus 1Sirolimus 1Saline Solution 1Rituximab 1Prednisone 1Ondansetron 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Sheba Medical Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡